Associate Professor Josh Davis

Principal research fellow

Qualifications:

PhD, Charles Darwin University, 2011; Bachelor of Medicine and Bachelor of Surgery, University of Sydney, 1994; Diploma of Tropical Medicine and Hygiene, University of Liverpool (UK), 1998; Graduate Diploma of Population Health, University of Newcastle, 2008; Fellow of the Royal Australasian College of Physicians in Infectious Diseases, 2005

Location:

Newcastle

Biography:

Josh is a clinician researcher, and divides his time between clinical work as an Infectious Diseases physician in Newcastle, and research work as a principal research fellow based at Menzies.

He completed his clinical infectious diseases training in 2004, and then worked on a PhD from 2007-2010 on the epidemiology, pathophysiology and adjunctive treatment of sepsis in the Top End of the Northern Territory (NT).

His main clinical interests are general infectious diseases, viral hepatitis, hepatology, HIV infection, refugee health and infections in the critical care setting. His main research interests are clinical trials in the management of severe infections and epidemiology of severe bacterial infections.

Josh is the vice president of the Australasian Society for Infectious Diseases (ASID) and is also the deputy chair of the ASID clinical research network. In 2015, Josh was awarded a prestigious career development fellowship from the NHMRC and also a $1 million project grant to conduct a randomised controlled trial investigating the use of combination antibiotic therapy for MRSA blood stream infection (the CAMERA study). 

 

  • Clinical trials: CAMERA (a randomised control trial or RCT of different antibiotic treatments for methicillin-resistant Staphylococcus aureus, MRSA, bacterium); CHARIOT (an RCT of adjunctive ibuprofen for cellulitis); and BLING (an RCT of continuous infusion vs bolus dosing of antibiotics for severe sepsis)
  • Hepatitis B virus (HBV): CHARM (molecular epidemiology of HBV in the Top End); ELEPHANT (epidemiology of liver cancer); developing an Ipad-based educational resource about HBV in Yolngu and English with partners from Galiwinku
  • Clinical epidemiology of severe bacterial infections: prospective Acinetobacter study; SANTA (Staphylococcus aureus in the Northern Territory of Australia); GUARDIAN (Group A Streptococcus bacteraemia in NT).
  1. Davis, J.S., Sud, A., O’Sullivan, M.V., Robinson, J.O., Ferguson, P.E., Foo, H., et al for the Combination Antibiotics for MEthicillin Resistant Staphylococcus Aureus (CAMERA) study group and the Australasian Society for Infectious Diseases Clinical Research Network.(2016). Combination of vancomycin and β-lactam therapy for methicillin resistant Staphylococcus aureus bacteremia: A pilot multicenter randomized controlled trial. Clinical Infectious Diseases, 62(2), 173-80.

  2. Dulhunty, J.M., Roberts, J.A., Davis, J.S., Webb, S.A., Bellomo, R., Gomersall, C., et al. (2015). A Multicenter Randomized Trial of Continuous versus Intermittent β-Lactam Infusion in Severe Sepsis. American Journal of Respiratory and Critical Care Medicine, 192(11), 1298-305.

  3. Tong, S., Davis, J., Eishenberger, E., Holland, T., & Fowler, V.G. (2015). Staphylococcus aureus Infections: Epidemiology, Pathophysiology, Clinical Manifestations, and Management. Clinical Microbiology Reviews, in press. Accepted 14/04/2015.

  4. Davis, J.S., He, V., Anstey, N.M., & Condon, J.R. (2014). Long term outcomes following hospital admission for sepsis using relative survival analysis: a prospective cohort study of 1,092 patients with 5 year follow up. PLoS ONE, 9(12), e112224.

  5. Parker, C., Tong, S., Dempsey, K., Condon, J., Sharma, S., Chen, J., Sievert, W., & Davis, J. (2014). Hepatocellular carcinoma in Australia's Northern Territory - high incidence and poor outcomes. Medical Journal of Australia, 201(8), 470-474.

  6. Davis, J., McMillan, M., Swaminathan, A., Kelly, J., Piera, K., Baird, R., et al. (2014). A 16-year prospective study of community-onset bacteremic Acinetobacter pneumonia: low mortality with appropriate initial empirical antibiotic protocols. Chest, 146(4): 1038-45.

  7. Deans, A., Boerma, C., De Souza, M., Fordyce, J., Palmer, D., & Davis J. (2013). Use of Royal Darwin Hospital Emergency Department by people in Immigration Detention during 2011. Medical Journal of Australiala,199 (11), 776-8.

  8. Dulhunty, J., Roberts, J., Davis, J., Webb, S., Bellomo, R., Gomersall C, et al. (2013). Continuous infusion of Beta-lactam antibiotics in severe sepsis: a multicenter double-blind, randomized controlled trial. Clinical Infectious Diseases, 56(2), 236-44.

  9. Davies, J., Gordon, C. L., Tong, S. Y. C., Baird, R. W., & Davis, J. S. (2012). Impact of results of a rapid staphylococcus aureus diagnostic test on prescribing of antibiotics for patients with clustered gram-positive cocci in blood cultures. Journal of Clinical Microbiology, 50(6), 2056-2058.
     
  10. Davies, J., Littlejohn, M., Locarnini, S. A., Whiting, S., Hajkowicz, K., Cowie, B. C., Davis, J. S. (2013). The molecular epidemiology of hepatitis B in the indigenous people of northern australia. Journal of Gastroenterology and Hepatology, 28(7), 1234-1241.
  1. Severe hep B strain afflicts indigenous population

    Severe hep B strain afflicts indigenous population

    Date

    INDIGENOUS Territorians with hepatitis B suffer from an aggressive strain of the virus not found anywhere else in the world, researchers from Menzies School of Health Research have found.

  2. Drug-Resistant Golden Staph Breakthrough Tested By Volunteer Australian Doctors

    Drug-Resistant Golden Staph Breakthrough Tested By Volunteer Australian Doctors

    Date

    When strains of the potentially deadly golden staph bacteria stopped responding to antibiotics in the 1960s, doctors scrambled to find a solution.

  3. Defeating serious MRSA infections using an everyday drug that shouldn’t work

    Defeating serious MRSA infections using an everyday drug that shouldn’t work

    Date

    A new drug combination is the first step towards improving treatment of drug resistant golden staph (MRSA) - a breakthrough that could potentially save hundreds of lives, every day.

  4. Infectious diseases specialist awarded $75 000 to continue fight against super-bug.

    Infectious diseases specialist awarded $75 000 to continue fight against super-bug.

    Date

    The grant will provide vital funding to develop trials in the areas of Staphylococcus aureus (golden Staph) infections, bone and joint infections and skin infections.

  5. Research reveals alarmingly high rates of the world’s second most deadly cancer in the NT

    Research reveals alarmingly high rates of the world’s second most deadly cancer in the NT

    Date

    A new study conducted by Menzies has found a very high prevalence of liver cancer in the NT.

  6. NHMRC career fellowship: Dr Josh Davis

    NHMRC career fellowship: Dr Josh Davis

    Date

    Menzies infectious diseases specialist, Dr Josh Davis was recently awarded a Career Development Fellowship as part of the National Health and Medical Research Council’s (NHMRC) yearly multi-million dollar funding round. Josh’s fellowship...

  7. NHMRC project snapshot: Dr Josh Davis

    NHMRC project snapshot: Dr Josh Davis

    Date

    Menzies infectious diseases specialist, Dr Josh Davis was recently awarded a competitive project grant as part of the National Health and Medical Research Council’s (NHMRC) yearly multi-million dollar funding round.

  8. NHMRC project snapshot: Dr Steve Tong

    NHMRC project snapshot: Dr Steve Tong

    Date

    Menzies' Post-doctoral Research Fellow Dr Steve Tong was recently awarded a competitive grant and a fellowship as part of the National Health and Medical Research Council's yearly multi-million dollar funding round.